Abstract
Introduction
Low-grade osteosarcoma encompasses parosteal osteosarcoma (POS) and low-grade central osteosarcoma (LCOS), with LCOS more rare than POS. LCOS is also more likely to be misdiagnosed and inappropriately treated with an intralesional procedure, due to its misleading radiological features and the overlap of its pathological characteristics with those of benign bone tumors. Therefore, as a diagnostic adjunct for LCOS, immunohistochemical assay with murine double-minute type 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) have been tried with controversial results. We investigated (1) the clinical course and surgical outcome of LCOS, and (2) the diagnostic role of immune-histochemical markers (CDK4, MDM2) and their correlation with clinico-radiologic findings.
Materials and methods
We retrospectively reviewed 16 LCOS patients with regard to age, gender, tumor location, plain radiographic pattern, tumor volume, extraosseous extension, initial diagnosis, initial treatment, definitive diagnosis, definitive treatment, surgical margins, histochemical markers, and oncological outcome.
Results
Final survival status was continuous disease-free in 14, alive with disease in 1, and remaining 1 patient died of other cancer. Except for 1 patient who had not undergone excision of their primary lesion, no patients developed a local recurrence. Eight tumors (50 %) showed diffuse immunostaining for CDK4. Three of 8 tumors labeled for CDK4 were also positive for MDM2. Six (75 %) of 8 CDK4-positive tumors displayed lytic lesions on a plain radiograph; in contrast, 2 (33 %) of 6 tumors showing a sclerotic pattern on a plain radiograph were positive for CDK4.
Conclusions
The diagnosis of LCOS is challenging; however, if it is properly diagnosed, there is a high chance of a cure with wide excision alone. Positive immunostaining for CDK4 or MDM2 may be used as a diagnostic adjunct, although negative immunostaining cannot rule out this tumor. The clinical, radiological, and typical pathological findings are vital in raising the suspicion of this rare tumor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Schwab JH, Antonescu CR, Athanasian EA, Boland PJ, Healey JH, Morris CD. A comparison of intramedullary and juxtacortical low-grade osteogenic sarcoma. Clin Orthop Relat Res. 2008;466(6):1318–22.
Kurt AM, Unni KK, McLeod RA, Pritchard DJ. Low-grade intraosseous osteosarcoma. Cancer. 1990;65(6):1418–28.
Okada K, Frassica FJ, Sim FH, Beabout JW, Bond JR, Unni KK. Parosteal osteosarcoma. A clinicopathological study. J Bone Joint Surg Am. 1994;76(3):366–78.
Campanacci M, Picci P, Gherlinzoni F, Guerra A, Bertoni F, Neff JR. Parosteal osteosarcoma. J Bone Joint Surg Br. 1984;66(3):313–21.
Muramatsu K, Hashimoto T, Seto S, Gondo T, Ihara K, Taguchi T. Low-grade central osteosarcoma mimicking fibrous dysplasia: a report of two cases. Arch Orthop Trauma Surg. 2008;128(1):11–5.
Franceschina MJ, Hankin RC, Irwin RB. Low-grade central osteosarcoma resembling fibrous dysplasia. A report of two cases. Am J Orthop (Belle Mead NJ). 1997;26(6):432–40.
Kenan S, Ginat DT, Steiner GC. Dedifferentiated high-grade osteosarcoma originating from low-grade central osteosarcoma of the fibula. Skeletal Radiol. 2007;36(4):347–51.
Choong PF, Pritchard DJ, Rock MG, Sim FH, McLeod RA, Unni KK. Low grade central osteogenic sarcoma. A long-term follow-up of 20 patients. Clin Orthop Relat Res. 1996;322:198–206.
Andresen KJ, Sundaram M, Unni KK, Sim FH. Imaging features of low-grade central osteosarcoma of the long bones and pelvis. Skeletal Radiol. 2004;33(7):373–9.
Bertoni F, Bacchini P, Fabbri N, Mercuri M, Picci P, Ruggieri P, Campanacci M. Osteosarcoma. Low-grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. Cancer. 1993;71(2):338–45.
Kumar A, Varshney MK, Khan SA, Rastogi S, Safaya R. Low grade central osteosarcoma—a diagnostic dilemma. Joint Bone Spine. 2008;75(5):613–5.
Malhas AM, Sumathi VP, James SL, Menna C, Carter SR, Tillman RM, Jeys L, Grimer RJ. Low-grade central osteosarcoma: a difficult condition to diagnose. Sarcoma. 2012;16:764–96.
Hayashi K, Tsuchiya H, Yamamoto N, Shirai T, Nishida H, Takeuchi A, Kimura H, Miwa S, Inatani H, Okamoto H, Yamada S, Ikeda H, Sawada-Kitamura S, Nojima T, Ooi A, Otsuka T. Diagnosis and treatment of low-grade osteosarcoma: experience with nine cases. Int J Clin Oncol. 2014;19(4):731–8.
Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M, Tsuda H. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010;23(9):1279–88.
Gamberi G, Ragazzini P, Benassi MS, Ferrari C, Sollazzo MR, Molendini L, Merli M, Magagnoli G, Ruggieri P, Balladelli A, Orlando C, Bacchini P, Pazzagli M, Picci P. Analysis of 12q13-15 genes in parosteal osteosarcoma. Clin Orthop Relat Res. 2000;377:195–204.
Park HR, Jung WW, Bertoni F, Bacchini P, Park JH, Kim YW, Park YK. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma. Pathol Res Pract. 2004;200(6):439–45.
Wunder JS, Eppert K, Burrow SR, Gokgoz N, Bell RS, Andrulis IL. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene. 1999;18(3):783–8.
Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, Muret Ad, Louis-Brennetot C, Aurias A, Coindre JM, Pedeutour L, Guillou F, Duval H, Collin C, de Pinieux G. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. 2011;24(5):624–37.
Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24.
Tarkkanen M, Bohling T, Gamberi G, Ragazzini P, Benassi MS, Kivioja A, Kallio P, Elomaa I, Picci P, Knuutila S. Comparative genomic hybridization of low-grade central osteosarcoma. Mod Pathol. 1998;11(5):421–6.
Antonescu CR, Huvos AG. Low-grade osteogenic sarcoma arising in medullary and surface osseous locations. Am J Clin Pathol. 2000;114(Suppl):S90–S103 (Review).
Gisselsson D, Palsson E, Hoglund M, Domanski H, Mertens F, Pandis N, Sciot R, Dal Cin P, Bridge JA, Mandahl N. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer. 2002;33(2):133–40.
Song WS, Jeon DG, Kong CB, Cho WH, Lee SY. Outcome of re-excision for intralesionally treated parosteal osteosarcoma. J Surg Oncol. 2011;103(3):264–8.
Acknowledgments
This work was supported by a grant of the KRP (KCCH Research Competence Promotion), Korea Institute of Radiological and Medical Sciences (50247-2014).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Jeon, DG., Koh, J.S., Cho, W.H. et al. Clinical outcome of low-grade central osteosarcoma and role of CDK4 and MDM2 immunohistochemistry as a diagnostic adjunct. J Orthop Sci 20, 529–537 (2015). https://doi.org/10.1007/s00776-015-0701-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00776-015-0701-0